

Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029

<https://marketpublishers.com/r/G6009E5C286FEN.html>

Date: June 2023

Pages: 900

Price: US\$ 3,600.00 (Single User License)

ID: G6009E5C286FEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029 Report Highlights:

Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029

Global & Regional Antibody Drug Conjugate Market Insight

Approved Drugs Sales Insight Global & Regional, Yearly & Quarterly, 2019-2023

Approved Antibody Drug Conjugates - Availability, Dosage & Price Insight

Insight On Antibody Drug Conjugates In Clinical Trials: > 550 Drugs

Insight On Commercially Approved Antibody Drug Conjugates: > 15 Drugs

Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase

Global Cancer Antibody Drug Conjugate Market Trends by Indication

The realm of cancer treatment is experiencing a surge of innovation that may greatly

Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook...

change how we currently diagnose as well as treat cancer. Clinical researchers and pharmaceutical companies continue to seek innovative solutions that offer enhanced efficacy and reduced side effects. Among the ongoing significant advancements, antibody drug conjugates (ADCs) have emerged as a groundbreaker in cancer therapeutics. This rapidly expanding market is transforming the treatment landscape, offering a new therapeutic option for patients globally.

Antibody drug conjugates harness the synergistic potential of monoclonal antibodies and potent cytotoxic drugs, delivering a strong strike against cancer cells. By exploiting the specificity of monoclonal antibodies, antibody drug conjugates can selectively bind to cancer antigens, increasing drug delivery directly to tumor sites. This targeted approach enables higher drug concentrations at the desired location while minimizing harm to healthy, normal tissues.

The antibody drug conjugate market is experiencing remarkable growth, driven by several key factors including the increasing cancer incidence rates, growing demand for effective and personalized treatment options and advancements in antibody engineering and drug delivery technologies are propelling the market forward. Moreover, regulatory approvals have opened the way for the commercial success of antibody drug conjugates which has further encouraged investments in the field.

For instance, Adcetris and Kadcyla have been in the market for a long time and their commercial sales hold a significant share of the current antibody drug conjugate market. The growth of these antibody drug conjugates represents the significant need for this therapeutic modality. Enhertu, another antibody drug conjugate which is relatively new to the market compared to Kadcyla and Adcetris, has shown immense success commercially. With its recent approval for breast cancer indication, the sales for Enhertu have escalated rapidly.

Antibody drug conjugates have welcomed a new age of targeted cancer therapy and this novel class of cancer treatment can be evaluated to have an exponential increase in terms of both commercial success as well as expansion of the global portfolio. However, the development of antibody drug conjugates has been associated with significant challenges with difficulties in manufacturing, bioconjugation and their overall development. Nevertheless, collaboration between pharmaceutical companies and academic institutions has been an important factor that has helped in overcoming these limitations, resulting in such success of antibody drug conjugates.

For instance, Lantern Pharma collaborating with Germany's Bielefeld University will

leverage its proprietary Artificial Intelligence platform RADR for the rapid development of novel cryptophycin antibody drug conjugates, representing an exciting new class of strong and highly directed drug candidates. It is expected that outcomes from this collaborative arrangement will pave the way for next generation antibody drug conjugated designed using AI with high efficacy, swift development with sibilant cost reduction.

The future of antibody drug conjugates is expected to be closely tangled with technological innovations. Novel conjugation strategies such as site specific conjugation are also being explored to enhance stability of antibody drug conjugates, resulting in improved therapeutic outcomes. Additionally, advancements in bioconjugation techniques, payload release mechanism and drug delivery systems offer opportunities to optimize the pharmacokinetics and bio distribution of antibody drug conjugates potentially increasing their effectiveness.

Antibody drug conjugates have targeted a new level of efficacy, surpassing the capabilities of traditional monoclonal antibodies and opening opportunities for market expansion. While monoclonal antibodies are highly specific in their binding to cancer cell antigens, their therapeutic impact often relies on the activation of immune responses or blocking signaling pathways. In contrast, antibody drug conjugates offer a multifaceted approach by directly delivering a potent cytotoxic payload to cancer cells, exerting a direct cell killing effect.

Overall, the antibody drug conjugates market represents a groundbreaking approach to cancer treatment. As market continues to expand, patients and healthcare professionals are witnessing significant advancements. With ongoing research, technological innovations and strategic collaborations, the future of antibody drug conjugates is set to transform the global cancer therapy market. Our report provides a comprehensive analysis about the currently approved antibody drug conjugates in terms of their patent, price, dosage as well as their sales and treatment cost. Furthermore, the report also provides information about the regional impact of approved antibody drug conjugates while also providing information about the possible future opportunities in the global antibody drug conjugates market.

Contents

1. INTRODUCTION TO ANTIBODY DRUG CONJUGATES

- 1.1 Overview
- 1.2 Historical Development of ADCs
- 1.3 Evolution of Antibody Drug Conjugates

2. NEED OF ANTIBODY DRUG CONJUGATES

3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET INSIGHT

- 3.1 Current Market Scenario (2019 -2023)
- 3.2 Future Market Opportunity Assessment 2029

4. ANTIBODY DRUG CONJUGATE MARKET REGIONAL ANALYSIS

- 4.1 US
- 4.2 China
- 4.3 South Korea
- 4.4 India
- 4.5 Australia
- 4.6 Europe
- 4.7 Canada
- 4.8 Japan
- 4.9 Taiwan

5. GLOBAL CANCER ANTIBODY DRUG CONJUGATE MARKET TRENDS BY INDICATION

- 5.1 Breast Cancer
- 5.2 Lung Cancer
- 5.3 Lymphoma
- 5.4 Leukemia
- 5.5 Cervical Cancer
- 5.6 Urothelial Cancer
- 5.7 Gastric Cancer
- 5.8 Other Cancers

6. APPROVED ANTIBODY DRUG CONJUGATES - AVAILABILITY, DOSAGE & PRICE INSIGHT 2023

- 6.1 Mylotarg
- 6.2 Adcetris
- 6.3 Kadcyła
- 6.4 Besponsa
- 6.5 Lumoxiti
- 6.6 Polivy
- 6.7 Padcev
- 6.8 Enhertu
- 6.9 Trodelvy
- 6.10 Blenrep
- 6.11 Zynlonta
- 6.12 Tivdak
- 6.13 Elahere
- 6.14 Aidixi
- 6.15 Ujvira
- 6.16 Akalux

7. APPROVED ANTIBODY DRUG CONJUGATE SALES INSIGHTS (GLOBAL & REGIONAL, YEARLY & QUARTERLY, 2019 -2023)

- 7.1 Adcetris
- 7.2 Padcev
- 7.3 Tivdak
- 7.4 Polivy
- 7.5 Kadcyła
- 7.6 Besponsa
- 7.7 Enhertu
- 7.8 Trodelvy
- 7.9 Zynlonta
- 7.10 Elahere
- 7.11 Blenrep

8. GLOBAL ANTIBODY DRUG CONJUGATES CLINICAL TRIALS INSIGHT 2023

- 8.1 By Phase
- 8.2 By Indication

8.3 By Company

8.4 By Patient Segment

8.5 By Country

9. GLOBAL CANCER ANTIBODY DRUG CONJUGATES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

9.1 Research

9.2 Preclinical

9.3 Phase-I

9.4 Phase-I/II

9.5 Phase-II

9.6 Phase-II/III

9.7 Phase-III

9.8 Preregistration

10. MARKETED CANCER ANTIBODY DRUG CONJUGATES CLINICAL INSIGHT

11. GLOBAL CANCER AN ANTIBODY DRUG CONJUGATES MARKET DYNAMICS

11.1 Favorable Parameters

11.2 Challenges for Antibody Drug conjugates Market

12. COMPETITIVE LANDSCAPE

12.1 AbbVie

12.2 ADC Therapeutics

12.3 AstraZeneca

12.4 Bayer

12.5 BiOneCure Therapeutics

12.6 Biosion

12.7 Bio-Thera Solutions

12.8 Boehringer Ingelheim

12.9 Daiichi Sankyo Company

12.10 Duality Biologics

12.11 Exelixis

12.12 Genmab

12.13 Hangzhou DAC Biotech

12.14 Heidelberg Pharma AG

- 12.15 Iksuda Therapeutics
- 12.16 ImmunoGen
- 12.17 LaNova Medicines Limited
- 12.18 LegoChem Biosciences
- 12.19 Lepu Biopharma
- 12.20 Mersana Therapeutics
- 12.21 Molecular Templates
- 12.22 Multitude Therapeutics
- 12.23 NanoValent Pharmaceuticals
- 12.24 NewBio Therapeutics
- 12.25 Orum Therapeutics
- 12.26 ProfoundBio
- 12.27 Radiopharm Theranostics
- 12.28 Seagen
- 12.29 Sorrento Therapeutics
- 12.30 Sutro Biopharma

List Of Figures

LIST OF FIGURES

Figure 1-1: Historical Development of Antibody Drug Conjugates

Figure 1-2: Approval History of Commercially Available Antibody Drug Conjugates

Figure 1-3: Classification of Antibody Drug Conjugates

Figure 2-1: Therapeutic Index – Antibody Drug Conjugate vs. Cytotoxic Drug

Figure 3-1: Global – Antibody Drug Conjugate Market (US\$ Billion), 2019-2023*

Figure 3-2: Global – Sales of ADCs for Breast Cancer v/s other indications (%), 2022

Figure 3-3: Global – Antibody Drug Conjugate Market Forecast (US\$ Billion), 2023 – 2029

Figure 4-1: Tubulis - P5 Conjugation Platform Antibody

Figure 4-2: US – Sales of Cancer Antibody Drug Conjugates (US\$ Million), 2023

Figure 4-3: US – Sales of Cancer Antibody Drug Conjugates (%), 2023

Figure 4-4: US – Sales of Cancer Antibody Drug Conjugates (US\$ Million), 2022

Figure 4-5: US – Sales of Cancer Antibody Drug Conjugates (%), 2022

Figure 4-6: Pinot Bio - PINOT-ADCTM Platform Working Mechanism

Figure 4-7: Alteogen - NexMab™ ADC technology

Figure 4-8: Canada – Cancer Incidence & Death, 2021

Figure 4-9: Adcetris - Canada Patents Numbers Approval & Expiration Dates

Figure 4-10: Padcev - Canada Patents Approval & Expiration Dates

Figure 4-11: Polivy - Canada Patents Numbers Approval & Expiration Dates

Figure 4-12: Enhertu - Canada Patents Numbers Approval & Expiration Dates

Figure 4-13: Trodelvy - Canada Patents Numbers Approval & Expiration Dates

Figure 4-14: Japan – Cancer Incidence & Death, 2022

Figure 6-1: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year

Figure 6-2: Mylotarg – Approval Year by Region

Figure 6-3: UK - Cost of Supply of Mylotarg 5 mg Intravenous Powder (GBP/US\$), May'2023

Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US\$), May'2023

Figure 6-5: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML

Figure 6-6: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US\$), May'2023

Figure 6-7: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML

Figure 6-8: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)

Figure 6-9: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m²)

Figure 6-10: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US\$), May'2023

Figure 6-11: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, May'2023

Figure 6-12: US - Adcetris Orphan Drug Designation Approval Year by Indication

Figure 6-13: US - Adcetris FDA Approval Year by Indication

Figure 6-14: Adcetris - Approval Year by Region

Figure 6-15: Japan - Adcetris PMDA Approval Year by Indication

Figure 6-16: Adcetris - Patent Expiration by Region

Figure 6-17: Adcetris - Cost of Supply of Vial for Injection by Region (US\$), May'2023

Figure 6-18: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)

Figure 6-19: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US\$), May'2023

Figure 6-20: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)

Figure 6-21: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US\$), May'2023

Figure 6-22: Adcetris – Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US\$), May'2023

Figure 6-23: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)

Figure 6-24: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US\$), May'2023

Figure 6-25: US - Kadcyla FDA Approval Year by Indication

Figure 6-26: Kadcyla - Approval Years by Region

Figure 6-27: US - Kadcyla FDA Approval & Patent Expiration Year

Figure 6-28: US - Price for Single Unit of Kadcyla 100 mg & 160 mg Intravenous Powder for Injection (US\$), May'2023

Figure 6-29: UK - Price for Single Unit of Kadcyla 100 mg & 160 mg Intravenous Powder for Injection (GBP/US\$), May'2023

Figure 6-30: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)

Figure 6-31: Kadcyla – Average Cost of Single Treatment Cycle for Early Stage HER2 Breast Cancer in Human with Average Weight (US\$), May'2023

Figure 6-32: Kadcyla – Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)

Figure 6-33: Besponsa - Approval Year by Region

Figure 6-34: UK - Cost of Supply of Besponsa 0.9 mg Intravenous Powder (GBP/US\$), May'2023

Figure 6-35: Besponsa - Cost of Supply of Vial for Injection by Region (US\$), May'2023

Figure 6-36: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)

Figure 6-37: Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m²)

Figure 6-38: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US\$), May'2023

Figure 6-39: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment (US\$), May'2023

Figure 6-40: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)

Figure 6-41: Lumoxiti – Orphan Designation Years

Figure 6-42: Lumoxiti – Patent Expiry Years

Figure 6-43: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)

Figure 6-44: Lumoxiti – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US\$), May'2023

Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region

Figure 6-46: US - Polivy Orphan Drug Designation Approval & Exclusivity Year

Figure 6-47: Polivy - Approval Year by Region

Figure 6-48: US - Price for Single Unit of Polivy 30 mg & 140 mg Intravenous Powder for Injection (US\$), May'2023

Figure 6-49: UK - Price for Single Unit of Polivy 30 mg & 140 mg Intravenous Powder for Injection (GBP/US\$), May'2023

Figure 6-50: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)

Figure 6-51: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia with 30 mg Powder (US\$), May'2023

Figure 6-52: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia with 140 mg Powder (US\$), May'2023

Figure 6-53: Padcev - Approval Year by Region

Figure 6-54: US - Padcev FDA Approval & Patent Expiration Year

Figure 6-55: US - Price for Padcev 20 mg & 30 mg Intravenous Powder for Injection (US\$), May'2023

Figure 6-56: UK - Price for Padcev 20 mg & 30 mg Intravenous Powder for Injection (GBP/US\$), May'2023

Figure 6-57: Padcev – Average Cost of Single Dose & Single Treatment Cycle with 20 mg Powder (US\$), May'2023

Figure 6-58: Padcev – Average Cost of Single Dose & Single Treatment Cycle with 30 mg Powder (US\$), May'2023

Figure 6-59: Padcev – Recommended Minimum Dose & Dose after Reduction for Urothelial Cancer (mg/Kg)

Figure 6-60: Padcev – Recommended Maximum Dose & Dose after Reduction for Urothelial Cancer (mg)

Figure 6-61: Enhertu – FDA Orphan Drug Designation & Exclusivity Expiration Year

Figure 6-62: Enhertu - Approval Year by Region

Figure 6-63: US - Polivy FDA Approval Year by Indication

Figure 6-64: UK - Cost of Supply of Enhertu 100 mg Intravenous Powder (GBP/US\$), May'2023

Figure 6-65: Besponsa - Cost of Supply of Vial for Injection by Region (US\$), May'2023

Figure 6-66: Enhertu – Recommended Dose by Cancer Type (mg/Kg)

Figure 6-67: Enhertu – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), May'2023

Figure 6-68: Enhertu – Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)

Figure 6-69: Enhertu – Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)

Figure 6-70: US - Trodelvy FDA Approval by Indication

Figure 6-71: Trodelvy - Approval Year by Region

Figure 6-72: Trodelvy - Patent Expiration by Region

Figure 6-73: Trodelvy – Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US\$), May'2023

Figure 6-74: Trodelvy – Recommended Dose & Dose after Reduction (mg/Kg)

Figure 6-75: Blenrep – FDA & EMA Orphan Drug Designations

Figure 6-76: Blenrep – FDA & EMA Approval

Figure 6-77: Blenrep - Cost of Supply of 100 mg Intravenous Powder in US, EU & UK (US\$), May'2023

Figure 6-78: Blenrep – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), May'2023

Figure 6-79: Blenrep – Recommended Dose & Dose after Reduction (mg/Kg)

Figure 6-80: Zynlonta - FDA & EMA Orphan Drug Designation Years

Figure 6-81: Zynlonta - FDA & EMA Approval Years

Figure 6-82: Zynlonta – Recommended Dose for Initial & Subsequent Cycles (mg/kg)

Figure 6-83: Zynlonta – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), May'2023

Figure 6-84: Tivdak – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), May'2023

Figure 6-85: Tivdak – Recommended Dose & Dose after Reduction (mg/Kg)

Figure 6-86: US - Price per Unit & Single Supply of Elahere 100 mg/20 mL Intravenous

Solution (US\$), May'2023

Figure 6-87: UK - Price for Single Unit of Elahere 100 mg/20 mL Intravenous Solution (GBP/US\$), May'2023

Figure 6-88: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year

Figure 6-89: India - Price for Single Unit of Ujvira 100 mg & 160 mg Intravenous Powder for Injection (INR/US\$), May'2023

Figure 6-90: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100 mg Powder for Injection (INR/US\$), May'2023

Figure 6-91: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)

Figure 6-92: Ujvira – Cost of Single Treatment Cycle with 100 mg & 160 mg Powder for Early Stage HER2+ Breast Cancer (INR/US\$), May'2023

Figure 6-93: Ujvira – Recommended Dose After 1st & 2nd Dose Reduction (mg/m²)

Figure 6-94: Akalux - Sakigake Designation & PMDA Approval Year

Figure 7-1: Global - Adcetris Annual Sales (US\$ Million), 2019-2023

Figure 7-2: Global - Adcetris Quarterly Sales (US\$ Million), 2022

Figure 7-3: Global - Padcev Annual Sales (US\$ Million), 2019-2023

Figure 7-4: Global - Padcev Quarterly Sales (US\$ Million), 2022

Figure 7-5: Global - Tivdak Annual Sales (US\$ Million), 2021-2023

Figure 7-6: Global - Tivdak Quarterly Sales (US\$ Million), 2022

Figure 7-7: Global - Polivy Sales Values (US\$ Million), 2019-2023

Figure 7-8: Regional - Polivy Sales (US\$ Million), Q1'2023

Figure 7-9: Regional - Polivy Annual Sales (%), Q1'2023

Figure 7-10: Global - Polivy Quarterly Sales (US\$ Million), 2022

Figure 7-11: Regional - Polivy Annual Sales (US\$ Million), 2022

Figure 7-12: Regional - Polivy Annual Sales (%), 2022

Figure 7-13: US – Polivy Annual Sales (US\$ Million), 2019-2023

Figure 7-14: EU – Polivy Annual Sales (US\$ Million), 2020-2023

Figure 7-15: ROW - Polivy Annual Sales (US\$ Million), 2020-2023

Figure 7-16: US - Polivy Quarterly Sales (US\$ Million), 2022

Figure 7-17: Europe - Polivy Quarterly Sales (US\$ Million), 2022

Figure 7-18: ROW - Polivy Quarterly Sales (US\$ Million), 2022

Figure 7-19: Global - Kadcyla Annual Sales Value (US\$ Million), 2019-2023

Figure 7-20: Regional - Kadcyla Sales (US\$ Million), Q1'2023

Figure 7-21: Regional - Kadcyla Annual Sales (%), Q1'2023

Figure 7-22: Global - Kadcyla Quarterly Sales (US\$ Million), 2022

Figure 7-23: Regional - Kadcyla Annual Sales (US\$ Million), 2022

Figure 7-24: Regional - Kadcyla Annual Sales (%), 2022

Figure 7-25: US – Kadcyła Annual Sales (US\$ Million), 2019-2023
Figure 7-26: Europe – Kadcyła Annual Sales (US\$ Million), 2020-2023
Figure 7-27: ROW - Kadcyła Annual Sales (US\$ Million), 2020-2023
Figure 7-28: US - Kadcyła Quarterly Sales (US\$ Million), 2022
Figure 7-29: Europe - Kadcyła Quarterly Sales (US\$ Million), 2022
Figure 7-30: ROW - Kadcyła Quarterly Sales (US\$ Million), 2022
Figure 7-31: Global - Besponsa Annual Sales (US\$ Million), 2020-2023
Figure 7-32: Besponsa - Annual Sales by Region (US\$ Million), Q1'2023
Figure 7-33: Besponsa - Quarterly Sales by Region (%), Q1'2023
Figure 7-34: Global - Besponsa Quarterly Sales (US\$ Million), 2022
Figure 7-35: Regional - Besponsa Annual Sales (US\$ Million), 2022
Figure 7-36: Regional - Besponsa Annual Sales (%), 2022
Figure 7-37: US - Besponsa Quarterly Sales (US\$ Million), 2022
Figure 7-38: US - Besponsa Annual Sales (US\$ Million), 2020-2023
Figure 7-39: Europe - Besponsa Quarterly Sales (US\$ Million), 2022
Figure 7-40: Europe - Besponsa Annual Sales (US\$ Million), 2020-2023
Figure 7-41: ROW - Besponsa Quarterly Sales (US\$ Million), 2022
Figure 7-42: ROW - Besponsa Annual Sales (US\$ Million), 2020-2023
Figure 7-43: Global - Enhertu Annual Sales (US\$ Million), 2020-2023
Figure 7-44: Global - Enhertu Quarterly Sales (US\$ Million), 2022
Figure 7-45: US - Enhertu Annual Sales (US\$ Million), 2020-2023
Figure 7-46: US - Enhertu Quarterly Sales (US\$ Million), 2022
Figure 7-47: Europe - Enhertu Annual Sales (US\$ Million), 2020-2023
Figure 7-48: Europe - Enhertu Quarterly Sales (US\$ Million), 2022
Figure 7-49: Japan - Enhertu Annual Sales (US\$ Million), 2020-2023
Figure 7-50: Japan - Enhertu Quarterly Sales (US\$ Million), 2022
Figure 7-51: Global - Trodelvy Annual Sales (US\$ Million), 2020-2023
Figure 7-52: Global - Trodelvy Quarterly Sales (US\$ Million), 2022
Figure 7-53: Regional - Trodelvy Annual Sales (%), 2022
Figure 7-54: Regional - Trodelvy Annual Sales (%), 2022
Figure 7-55: US - Trodelvy Annual Sales (US\$ Million), 2020-2023
Figure 7-56: US - Trodelvy Quarterly Sales (US\$ Million), 2022
Figure 7-57: Europe - Trodelvy Annual Sales (US\$ Million), 2021-2023
Figure 7-58: Europe - Trodelvy Quarterly Sales (US\$ Million), 2022
Figure 7-59: ROW - Trodelvy Annual Sales (US\$ Million), 2022-2023
Figure 7-60: ROW - Trodelvy Quarterly Sales (US\$ Million), 2022
Figure 7-61: Global - Zynlonta Annual Sales (US\$ Million), 2021-2023
Figure 7-62: Global - Zynlonta Quarterly Sales (US\$ Million), 2022
Figure 7-63: Global - Elahere Annual Sales (US\$ Million), 2022-2023

- Figure 7-64: Global - Blenrep Annual Sales (Euro/US\$ Million), 2020-2023
- Figure 7-65: Regional - Blenrep Sales (Euro/US\$ Million), Q1'2023
- Figure 7-66: Regional – Blenrep Annual Sales (Euro/US\$ Million), 2022
- Figure 7-67: Regional – Blenrep Annual Sales (%), 2022
- Figure 7-68: Global - Blenrep Quarterly Sales (Euro/US\$ Million), 2022
- Figure 7-69: US - Blenrep Annual Sales (Euro/US\$ Million), 2020-2023
- Figure 7-70: US - Blenrep Quarterly Sales (Euro/US\$ Million), 2022
- Figure 7-71: Europe - Blenrep Annual Sales (Euro/US\$ Million), 2020-2023
- Figure 7-72: Europe - Blenrep Quarterly Sales (Euro/US\$ Million), 2022
- Figure 8-1: Global – Antibody Drug Conjugate In Clinical Trials By Phase, 2023
- Figure 8-2: Global– Antibody Drug Conjugate In Clinical Trials By Indication, 2023
- Figure 8-3: Global – Antibody Drug Conjugate In Clinical Trials By Company, 2023
- Figure 8-4: Global – Antibody Drug Conjugate In Clinical Trials By Patient Segment, 2023
- Figure 8-5: Global Antibody Drug Conjugate In Clinical Pipeline By Country, 2023
- Figure 11-1: Antibody Drug conjugates Market Drivers
- Figure 11-2: Challenges for Antibody Drug conjugates Market

List Of Tables

LIST OF TABLES

Table 3-1: Approved Cancer Antibody Drug Conjugates

Table 5-1: Breast Cancer – Candidates Under Clinical Development

Table 5-2: Lung Cancer – Some Candidates under Clinical development

Table 5-3: Lymphoma – Some Candidates under Clinical development

Table 5-4: Leukemia – Some Candidates under Clinical development

Table 5-5: Urothelial Cancer – Some Candidates under Clinical development

Table 5-6: Gastric Cancer – Some Candidates under Clinical development

Table 5-7: Recent FDA/EMA Designations to Investigational ADCs

I would like to order

Product name: Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029

Product link: <https://marketpublishers.com/r/G6009E5C286FEN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6009E5C286FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

